Best Celula Podcasts (2025)

1
Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales 25:12

14d ago25:12

25:12

Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.

1
Episode 406: Drug Development in China: Part 1 of 2 30:02

3h ago30:02

30:02

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

1
Episode 405: The Good News About Cancer podcast 17:53

3d ago17:53

17:53

Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.

1
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands 27:09

7d ago27:09

27:09

Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.

1
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands 37:41

12d ago37:41

37:41

Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer

1
Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands 30:29

16d ago30:29

30:29

Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.

1
Episode 400: The Uromigos Score for Urothelial Cancer 20:19

17d ago20:19

20:19

Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.

1
Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers? 36:44

21d ago36:44

36:44

Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.

1
Episode 398: Reflections on the Felix Feng Symposium at ASCO GU 32:05

28d ago32:05

32:05

Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.

1
Episode 397: APCCC Diagnostics Conference recap 43:15

1M ago43:15

43:15

Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025

1
Episode 396: Uromigos Japan - 激論 @JSMO25 29:49

1M ago29:49

29:49

尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?

1
Episode 395: Uromigos Japan: ASCO GU 2025のレビュー 31:24

1M ago31:24

31:24

ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！

1
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025 30:27

1M ago30:27

30:27

Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)

1
Episode 393: ASCO GU 2025 Review Podcast 46:06

2M ago46:06

46:06

Silke joins Tom and Brian to discuss highlights form ASCO GU 2025

1
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC 30:09

2M ago30:09

30:09

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

1
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214 23:28

2M ago23:28

23:28

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

1
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update 30:03

2M ago30:03

30:03

Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data

1
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer 25:28

2M ago25:28

25:28

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

1
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results 27:07

2M ago27:07

27:07

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.

1
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes 28:23

2M ago28:23

28:23

Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.

1
Episode 386: ASCO GU 2025 - APRI Meta-analysis 28:58

2M ago28:58

28:58

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2

1
Episode 385: ASCO GU 2025 - TALAPRO-2 32:01

2M ago32:01

32:01

Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data

1
Episode 384: ASCO GU Preview 35:23

2M ago35:23

35:23

Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.

1
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC 33:11

2M ago33:11

33:11

David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine

1
Episode 382: Uromigos Japan - TROPICs-04の考察 29:48

2M ago29:48

29:48

残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします！！

1
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade 40:05

3M ago40:05

40:05

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

1
Episode 380: The Role of SBRT in RCC 42:02

3M ago42:02

42:02

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

1
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る 31:31

3M ago31:31

31:31

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！

1
Episode 378: 2025 Preview of Important GU Data 41:42

3M ago41:42

41:42

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer

1
Episode 377: Prostate Cancer 2024 Highlights 35:12

4M ago35:12

35:12

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.

1
Episode 376: Bladder Cancer 2024 Highlights 25:37

4M ago25:37

25:37

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

1
Episode 375: Renal Cancer 2024 Highlights 43:11

4M ago43:11

43:11

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

1
Episode 374: Mechanisms of HIF Resistance 34:37

4M ago34:37

34:37

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

1
Episode 373: KEYNOTE-564 Asian OSとANNARの解説 34:05

4M ago34:05

34:05

JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです

1
Episode 372: FDA Accelerated Approval Process 31:30

4M ago31:30

31:30

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.

1
Episode 371: TROPICS-04 Results from ESMO Asia 33:43

4M ago33:43

33:43

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

1
Episode 370: Artificial Intelligence in Medical Oncology 44:46

4M ago44:46

44:46

Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology

1
Episode 369: Paper of the Month with Bishoy Faltas 45:51

5M ago45:51

45:51

Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication

1
Episode 368: Radiomics in RCC: Live from IKCS 37:00

5M ago37:00

37:00

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

1
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer 56:48

5M ago56:48

56:48

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

1
Episode 366: ARPIs in Prostate Cancer - Are They Different? 31:51

5M ago31:51

31:51

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

1
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC) 47:59

6M ago47:59

47:59

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

1
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜 15:41

6M ago15:41

15:41

腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

1
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜 14:23

6M ago14:23

14:23

前立腺がんの最新の話題〜T cell directed therapyとradioligands〜

1
Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜 12:42

6M ago12:42

12:42

膀胱がんの最新の話題〜周術期薬物療法とADC〜

1
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer 25:43

6M ago25:43

25:43

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

1
Episode 360: The SUNRISE Program in Bladder Cancer 46:19

6M ago46:19

46:19

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

1
Episode 359: #UromigosLive24 - IO after IO in RCC 40:41

6M ago40:41

40:41

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville 21:59

7M ago21:59

21:59

Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…

1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer 1:03:10

7M ago1:03:10

1:03:10

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

Podcasts Worth a Listen

Celula Podcasts

Podcasts Worth a Listen

Quick Reference Guide